Ataul Qureshi, MD
Advanced Heart Failure and Transplant Cardiology · Canton, OHNPI 1992013338
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,907 of the $6,467 with a category attached, or 60.4%. Abbott accounts for 71.2% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $4,020, 2.4 times the $1,642 reported in 2019.
Across 84 payments — averaging $76.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Abiomed$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$174
- Edwards Lifesciences$61
- AstraZeneca$48
- Alnylam Pharmaceuticals Inc.$35
- plus $178 from 9 others
Across 24 payments — averaging $11,515 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$197K
- Novartis$54K
- Eli Lilly$13K
- AstraZeneca$12K
What the payments were for
- Travel & lodging$3,90760%
- Food & beverage$2,49239%
- Education$691%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 48 | $4,603 |
| Abiomed | 13 | $1,367 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $174 |
| Edwards Lifesciences | 1 | $61 |
| AstraZeneca | 2 | $48 |
| Alnylam Pharmaceuticals Inc. | 1 | $35 |
| Amgen | 2 | $29 |
| Sanofi | 1 | $24 |
| GE HealthCare | 1 | $22 |
| Merck | 2 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
| Livanova USA, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Novartis | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,467 in reported general payments places this provider in the 55th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 132 | $2,856,572 |
| EntrestoSacubitril/Valsartan | 927 | $1,035,705 |
| Tyvaso DpiTreprostinil | 34 | $811,054 |
| OpsumitMacitentan | 63 | $789,231 |
| AdempasRiociguat | 51 | $704,069 |
| JardianceEmpagliflozin | 546 | $558,922 |
| VyndaqelTafamidis Meglumine | 21 | $438,249 |
| UptraviSelexipag | 14 | $379,611 |
| EliquisApixaban | 401 | $351,923 |
| FarxigaDapagliflozin Propanediol | 48 | $51,148 |
| XareltoRivaroxaban | 26 | $30,136 |
| Tadalafil | 50 | $12,742 |
| Bumetanide | 272 | $8,213 |
| Metoprolol Succinate | 591 | $7,025 |
| Torsemide | 202 | $3,748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $15 | $1,035,705927 claims |
| Boehringer IngelheimJardiance | $18 | $558,922546 claims |
| AstraZenecaFarxiga | $48 | $51,14848 claims |
| Johnson & JohnsonXarelto | $12 | $30,13626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Canton
- Pei Jun ZhaoCanton$4K
- William AbrahamColumbus$802K
- Rami KahwashColumbus$379K
- Eugene ChungCincinnati$297K
- Kenneth VarianAkron$170K
- Ankit BhatiaCincinnati$141K
- Rachel GarciaCincinnati$104K
- Sateesh KesariCincinnati$101K
- Sitaramesh EmaniCincinnati$87K
- Gregory EgnaczykCincinnati$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.